

# Clementina Maria Galluzzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7847474/publications.pdf>

Version: 2024-02-01

42  
papers

640  
citations

623188

14  
h-index

610482

24  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi. <i>Medical Microbiology and Immunology</i> , 2018, 207, 175-182.	2.6	3
2	Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1218-1223.	1.1	14
3	Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. <i>HIV Medicine</i> , 2017, 18, 440-443.	1.0	8
4	Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis. <i>HIV Clinical Trials</i> , 2016, 17, 49-54.	2.0	10
5	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1027-1030.	1.3	32
6	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 737-742.	0.5	9
7	Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3206-3211.	1.3	5
8	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. <i>Clinical Microbiology and Infection</i> , 2016, 22, 818-820.	2.8	2
9	HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy. <i>Journal of Medical Virology</i> , 2016, 88, 2115-2124.	2.5	7
10	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. <i>Infectious Diseases</i> , 2016, 48, 317-321.	1.4	6
11	Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi. <i>Journal of Tropical Pediatrics</i> , 2015, 61, 222-225.	0.7	0
12	Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2881-2884.	1.3	4
13	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 71-77.	0.5	9
14	Anti- <i>Streptococcus pneumoniae</i> and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. <i>Journal of Medical Microbiology</i> , 2015, 64, 795-797.	0.7	2
15	Viral Sequence Analysis of HIV-Positive Women and Their Infected Children: Insight on the Timing of Infection and on the Transmission Network. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1010-1015.	0.5	4
16	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 749-752.	1.3	2
17	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	1.3	13
18	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e109791.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1365-1369.	0.5	2
20	Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1479-1485.	1.3	10
21	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. <i>Antiviral Therapy</i> , 2012, 17, 1511-1519.	0.6	37
22	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. <i>Cytokine</i> , 2012, 57, 54-60.	1.4	6
23	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. <i>Journal of Medical Virology</i> , 2012, 84, 1553-1557.	2.5	13
24	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. <i>Journal of Virological Methods</i> , 2010, 168, 272-276.	1.0	15
25	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 541-545.	0.5	7
26	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 707-711.	0.5	9
27	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. <i>HIV Medicine</i> , 2009, 10, 477-481.	1.0	11
28	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <math>50</math>copies/ml HIV-1 RNA. <i>Journal of Clinical Virology</i> , 2009, 46, 367-370.	1.6	54
29	Novel Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and Biological Activities. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4744-4750.	2.9	45
30	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. <i>Aids</i> , 2007, 21, 2360-2362.	1.0	10
31	Antiretroviral Resistance Mutations in Untreated Pregnant Women with HIV Infection in Uganda and Rwanda. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1449-1451.	0.5	8
32	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. <i>Retrovirology</i> , 2007, 4, 17.	0.9	20
33	Novel Bifunctional Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, Biological Activities, and Mechanism of Action. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1939-1945.	2.9	82
34	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3407-3417.	1.4	18
35	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 816-818.	0.5	13
36	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1760-1762.	1.8	28

#	ARTICLE	IF	CITATIONS
37	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3007-3012.	1.8	14
38	Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. <i>Aids</i> , 2003, 17, 1570-1572.	1.0	18
39	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	1.0	18
40	Quality of life outcomes of combination zidovudine+didanosine+nevirapine and zidovudine+didanosine for antiretroviral-naive advanced HIV-infected patients. <i>Aids</i> , 2000, 14, 2567-2574.	1.0	24
41	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment <sup>1</sup> . <i>Antiviral Research</i> , 2000, 47, 189-198.	1.9	13
42	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1809-1820.	0.5	9